CAS: 4469-80-1; 4-Propoxyaniline

该化合物是一种有机化合物,其特征是,在准位置上有一个有阴性成分组,代之以丙氧成分组;其分子结构包括一个苯环,该苯环系于一个氨基基组(-NH2)和一个丙氧基组(-O-CH2-CH2-CH2-CH3),该物质组影响其物理和化学特性;该化合物一般是一种无色的黄色液体或固体,视其纯度和温度而定;它溶于有机溶剂,并显示水中溶性;4-丙基苯胺可参与各种化学反应,包括生物电子代用和核生殖反应,由于该氨基组的存在,它经常用于染料,制药和农用化学合成;应当考虑安全因素,因为如果浸入或浸入,可能会对健康造成危害;实验室环境应遵循适当的处理程序.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号1568-66-7 1-(Allyloxy)-4-... | CAS号7244-77-1 p-propoxynitrob... | CAS号71-23-8 正丙醇 | CAS号540-37-4 对碘苯胺 | CAS号20367-32-2 N-(4-丙氧基苯基)乙酰胺 | CAS号100-02-7 对硝基苯酚 | CAS号100-17-4 4-硝基苯甲醚 | CAS号103-90-2 对乙酰氨基苯酚 | CAS号55792-12-6 2-piperidin-1-i... | CAS号1124-31-8 对硝基(苯)酚钾 | CAS号14921-37-0 N,1-bis(4-propo... | CAS号20367-32-2 N-(4-丙氧基苯基)乙酰胺 | CAS号14372-64-6 6-丙氧基-苯并噻唑-2-胺 | CAS号33228-21-6 (4-butylphenyl)... | CAS号87739-50-2 1,3,5-Triazine-... | CAS号89143-07-7 1-(4-propoxyphe... | CAS号89143-17-9 1-(4-propoxyphe... | CAS号89143-29-3 3-piperidin-1-y... | CAS号62178-47-6 1-(4-chlorophen...

合成工艺路线路线简述

  • 合成目标产物 4-Propoxyaniline 主要起始原料 1-(Allyloxy)-4-Nitrobenzene
  • (文献来源)合成步骤主要原料 1-(Allyloxy)-4-Nitrobenzene
📜1-硝基-4-丙氧基-苯置于甲烷 一水合肼体系中,用 乙醇 作为反应溶剂,化学反应 2.0H,以98%的收率获得产物对正丙氧基苯胺
参考文献:石墨与水合肼催化还原芳香族和脂肪族硝基化合物
标题:石墨与水合肼催化还原芳香族和脂肪族硝基化合物
摘要:用石墨和水合肼,芳族和脂肪族硝基化合物很容易以优异的产率还原为氨基化合物.
DOI:10.1016/s0040-4039(00)95060-3

海关参考信息

专利信息


专利号:US-11040938-B2
优先权日:2016-07-27
标 题 :Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts
发明人:MA BING; PAN SHUAI
权利人:SHANGHAI HYBRID—CHEM TECH; SHANGHAI HYBRID CHEM TECH
摘要:The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

专利号:US-3992392-A
优先权日:1973-04-27
标题:Synthesis of indoles from anilines and intermediates therein
发明人:GASSMAN PAUL G
权利人:UNIV OHIO STATE RES FOUND
摘要:Preparing indoles and intermediates therefor by reacting an N-haloaniline with a β-carbonylic hydrocarbon sulfide to form an azasulfonium halide, reacting the azasulfonium halide with a strong base to form a thio-ether indole derivative, and then reducing the thio-ether indole, e.g. with Raney nickel, to form the indole compound. When an acetal or ketal of the β-carbonyl hydrocarbon sulfide is used, the azasulfonium salt is treated with a base, and then with an acid to form the thio-ether indole derivative. When an α-ethyl-β -carbonylic hydrocarbon sulfide is used, the resulting azosulfonium salt reacts with strong base to form a thio-ether indolenine derivative, which on reduction with Raney nickel or complex metal hydrides yields 3-substituted indoles. The aniline may be an aminopyridine to form an aza-indole compound in the process. The azasulfonium salts and thio-ether indole or thio-ether indolenine derivatives can be isolated and recovered from their respective reaction mixtures. The thio-ether-indole and thio-ether indolenine derivatives are useful as intermediates to make the indoles without the thio-ether group. The indoles are known compounds having a wide variety of uses, e.g., in making perfumes, dyes, amino acids, pharmaceuticals, agricultural chemicals and the like.

专利号:US-2019152896-A1
优先权日:2016-07-27
标题 :Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts

专利号:US-7737159-B2
优先权日:2004-01-21
标 题:Antibacterial compounds
发明人:ANDERSON DAVID D; BEUTEL BRUCE A; COOPER CURT S; GU YU-GUI; HINMAN MIRA M; KALVIN DOUGLAS M; KEYES ROBERT F; SEARLE XENIA B; WAGNER ROLF
权利人:ABBOTT LAB
摘要:Bacterial protein synthesis-inhibiting compounds having formula (I) n n n n n n n n n n and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献


参考文献:10.1126/science.abo7201
摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知